| Chemical Information | |
| Antiviral agent ID | DrugRepV_7070 | |
| Antiviral agent name | Amodiaquine derivative (AQD2) | |
| Structural Information | |
| 2-D Structure is not available | 3-D Structure is not available |
| Clinical Information | |
|
Category | Antiparasitic products, Insectisides and Repellents
| |
| Biological Information | |
|
Primary Indication (Disease Category) | Infectious Disease
| |
|
Primary Indication (Disease) | Malaria
| |
|
Secondary Indication | West Nile virus (WNV) NA NA |   |
|
Secondary Indication (Approaches) | Experimental | |
| Secondary Indication (Methods) | in-vitro | |
|
Secondary Indication (Model system) [cell lines/ animal models] | Vero/WNV replicon
| |
|
Secondary Indication (Mode of viral infection) | Adsorption
| |
|
Secondary Indication (Viral titer) | 1 MOI
| |
|
Secondary Indication (Mode of drug delivery) | Culture
| |
|
Secondary Indication (Time of drug delivery) | Post infection
| |
|
Secondary Indication (Duration of drug delivery) | 24 hours
| |
|
Secondary Indication (Drug concentration) | 50 μM
| |
|
Secondary Indication (Cell based assay) | Plaque assay
| |
|
Secondary Indication (Change) | Decrease
| |
|
Secondary Indication (Type of Inhibition) | Percentage Inhibition [ 50 % ] | |
|
Reference | Boonyasuppayakorn S, Reichert ED, Manzano M, Nagarajan K, Padmanabhan R..Amodiaquine, an antimalarial drug, inhibits dengue virus type 2 replication and infectivity..Antiviral Res. 2014 Jun;106:125-34. doi: 10.1016/j.antiviral.2014.03.014. Epub 2014 Mar 27. PMID:24680954
|  |
|
Comment | Both phydroxyanilino and diethylaminomethyl moieties are important for amodiaquine to inhibit DENV2 replication and infectivity. Thus it is a promising candidate for anti-flaviviral therapy.
| |